Drug
Integrase Inhibitor
Integrase Inhibitor is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_4
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 4Post-market surveillance
3(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Phase 43 (100.0%)
Trials by Status
terminated133%
completed133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_4
Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection
NCT02691065
recruitingphase_4
Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI
NCT06602622
terminatedphase_4
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
NCT00488059
Clinical Trials (3)
Showing 3 of 3 trials
NCT02691065Phase 4
Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection
NCT06602622Phase 4
Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI
NCT00488059Phase 4
A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3